Stock Ratings / Health Care / LTRN / options

BLRX (46) TPST (34) CALC (38) PHIO (37) ⌘ Pro Terminal →

Lantern Pharma Inc. (LTRN) Options Positioning, Max Pain & Unusual Sweeps

$0.66 -9.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.65

Lantern Pharma Inc. (LTRN) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $9.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LTRN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LTRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lantern Pharma Inc. (NASDAQ: LTRN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.66 (-9.60% 1D, market cap $9.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LTRN ranks #777 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LTRN compare to BLRX and TPST in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTRN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $9.9M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, LTRN leads on earnings multiple (N/A) while LTRN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LTRN?

▼

Per LTRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001763950), Lantern Pharma Inc. generated $0 in revenue, -$17.1M in net income, and -$15.7M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.65 (-1.92%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTRN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY LTRN SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.71-7% Next Q

Q2 (-2Q)

Grade E$0.66-3% Next Q

Q3 (-1Q)

Grade E$0.64+3.1% Next Q

Current

Grade E$0.66-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LTRN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LTRN currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($0.69) forces dealer call-delta covering toward $4.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LTRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LTRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LTRN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LTRN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTRN)

✓Walkthrough of LTRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LTRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.40%⚡ TESTING RESISTANCE

2026-11-03O $0.73H $0.73L $0.66C $0.66VOL 218.5K

RES: $0.71SUP: $0.50SMA50: $1.23SMA200: $2.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LTRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LTRN Butterfly Map → + Track LTRN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LTRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LTRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LTRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTRN)

Health Care Rank #777 of 1016 ⚔️ BLRX vs LTRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LTRN vs. BLRX, TPST, CALC, PHIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lantern Pharma Inc. (LTRN) ranks #777 by composite RQD confidence (31/100, grade E) and #895 by equity capitalization ($9.9M). Within this direct 5-issuer industry benchmark cohort, LTRN leads on earnings valuation at N/A trailing P/E, while LTRN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with LTRN at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LTRN ACTIVE Lantern Pharma Inc.	E	31/100	—	—	-35.0%	-9.60%	$9.9M	Benchmark Subject
BLRX BioLineRx Ltd.	D	46/100	—	—	—	-1.48%	$9.9M	/blrx-vs-ltrn →
TPST Tempest Therapeutics Inc.	E	34/100	—	—	-35.0%	-7.07%	$9.9M	/tpst-vs-ltrn →
CALC CalciMedica Inc.	D-	38/100	—	—	-35.0%	-16.57%	$10.0M	/calc-vs-ltrn →
PHIO Phio Pharmaceuticals Corp.	D-	37/100	—	—	-35.0%	-0.30%	$10.0M	/phio-vs-ltrn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001763950

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lantern Pharma Inc. (LTRN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$17.1M, operating cash flow of -$15.7M, and free cash flow of -$15.7M (+12.0% YoY). On the balance sheet, LTRN closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$17.1M	-$15.7M	-$15.7M	$11.0M	—
FY2024 (FY)	2024-12-31	$0	-$20.8M	-$17.8M	-$17.8M	$25.6M	—
FY2023 (FY)	2023-12-31	$0	-$16.0M	-$14.3M	-$14.3M	—	—

3. LTRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LTRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LTRN compare to BLRX and TPST in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LTRN?

Where is LTRN trading relative to its 50-day, 200-day, and 52-week technical levels?

LTRN last traded at $0.66 (-9.60% on volume of 218,539 shares), positioning the stock -46.34% below its 50-day simple moving average ($1.23) and -72.95% below its 200-day simple moving average ($2.44). Across its 52-week range of $0.59 to $4.34, LTRN sits at the 1.9% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).

LTRN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LTRN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for LTRN.

Direct Sub-Reports: LTRN RQD Cockpit LTRN 12M Forecast LTRN Earnings & Move LTRN Dividends & DRIP LTRN Insiders & 13F LTRN Whale Options LTRN Profit Sankey LTRN News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LTRN — Lantern Pharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:35Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns a score of 31 out of 100, a letter grade of E, and a verdict of "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 6 of 20, reflecting an ROIC of -35% and an FCF yield of 0%; for a prospective investor, this indicates the business is not currently generating returns on capital or free cash flow to support valuation. The whale 13F flow pillar scores 3 of 20 on institutional accumulation and options positioning, signaling weak institutional support in the source data. The insider conviction pillar scores 5 of 20 on SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 7 of 20 with a beta of 1.0 and sector sensitivity considerations. The forensic balance sheet pillar scores 10 of 20, with an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. Taken together, the rating points to elevated forensic and cash-generation risk. Upside drivers are not evident in the rating components; any valuation discussion must be weighed against negative ROIC and zero FCF yield. Prospective investors should treat the verdict as a risk-screening signal rather than a directional forecast.

Business

Lantern Pharma Inc. is listed on NASDAQ and classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company operates as a health care issuer in this industry with a market capitalization shown as $0.0B in the profile section and $10.9M in market data. The source data does not describe specific products, customers, or revenue model. Reported revenue across the financial periods is $0.0M.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-18.0M	$-17.1M	N/A	$-15.7M	$4.4M	N/A
FY 2024	$0.0M	$-22.2M	$-20.8M	N/A	$-17.8M	$7.5M	N/A
FY 2023	$0.0M	$-17.9M	$-16.0M	N/A	$-14.3M	N/A	N/A

Per the SEC financials, the company reported operating losses and net losses in each listed period, with negative free cash flow throughout. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and the Debt/Equity ratio is 0.5. Cash declined from $7.5M in FY 2024 to $4.4M in FY 2025 per the SEC financials. Debt values are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most recent items include a Moomoo options-chain report, a TradingView estimates report, and a Stock Titan item noting a reported stake that includes 212,554 shares issuable through warrants. A TradingView weekly recap is tagged as a CATALYST and references MVLS Nasdaq noncompliance and a $4M equity raise with warrants. Two items are tagged RISK WATCH or YELLOW and describe price declines, including a reported slip of 2.05% to $0.81 and a drop of 14% to $0.86. The final item is tagged RED. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.

Open Questions

What are the company's products, pipeline, and revenue sources, given that reported revenue is $0.0M?
What is the debt position, since debt figures are not available in source data?
What is the basis for the $4M equity raise and warrant issuance referenced in the news, and what is the expected dilution?
What is the status of the MVLS Nasdaq noncompliance matter referenced in the news?
What is the company's cash runway given cash of $4.4M against FY 2025 free cash flow of $-15.7M?

LTRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lantern Pharma Inc. (LTRN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LTRN Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 18h ago

Lantern Pharma(LTRN) Stock Options Chain | Quotes & News

Moomoo report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Lantern Pharma Inc. Estimates – NASDAQ:LTRN

TradingView report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A reported Lantern Pharma (LTRN) stake includes 212,554 shares issuable through warrants.

Stock Titan report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Weekly Recap: MVLS Nasdaq noncompliance and $4M equity raise with warrants

TradingView report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Lantern Pharma (LTRN) Slips 2.05% to $0.81, Drifting Toward Key Support - Break of Structure

https://www.siam.in/ report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

Lantern Pharma (LTRN) Drops 14% to $0.86, Testing Key Support Zone - Sweep Order Flow

https://www.dars.gov.et/ report covering Lantern Pharma Inc. (LTRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LTRN Bull vs. Bear Conversation Board — What's Your Call at $0.66?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LTRN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.64 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LTRN (E • RQD 31/100) a Buy at $0.73?

Welcome to the LTRN (Lantern Pharma Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.58 (-20.5%)

Spot @ $0.73

Pump the brakes on LTRN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LTRN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lantern Pharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.93 (+27.4%)

Spot @ $0.73

LTRN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LTRN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.73 (52-wk range $0.59 - $4.34), any beat on forward guidance forces shorts and underweight funds to chase.